


Press Release

IOL Chemicals and Pharmaceuticals Ltd consistently reports strong performance in Q2' FY21

6th November, 2020, Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals today once again posted strong performance in the second quarter of FY 2020-21.

A. Quarter ended September 2020 (Q2FY21) vis a vis Quarter ended September 2019 (Q2FY20)



Rs Crore

Particulars	Q2FY21	Q2FY20	% Change
Total income from operations	538	452	19%
EBIDTA	176	136	29%
Net Profit before Tax	165	121	36%
Net Profit after Tax	127	88	45%
EPS - in Rs (not Annualized)	21.61	15.42	40%

B. Half year ended September 2020 (H1FY21) vis a vis Half year ended September 2019 (H1FY20)

Rs Crore

Particulars	H1FY21	H1FY20	% Change
Total income from operations	1004	948	6%
EBIDTA	334	284	17%
Net Profit before Tax	312	252	24%
Net Profit after Tax	255	173	47%
EPS - in Rs (not Annualized)	43.91	30.42	44%

Mr Vijay Garg, Joint Managing Director said "We are very delighted to announce consistently strong operational and financial performance during the 2nd quarter of the Financial Year 2020-21 in spite of difficult period of pandemic Covid-19. We also pleased to inform that the Company has also declared an Interim Dividend @ 40% to the shareholders. He further said that we expect to continue the similar performance in coming periods.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.